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Abstract
Background: This open, multicentre, observational survey investigated how physicians diagnose
neuropathic pain (NeP) by applying the Leeds Assessment of Neuropathic Symptoms and Signs
(LANSS) scale, and how neuropathic pain conditions are managed in daily practice in Belgium.
Methods: Physicians were asked to complete the Leeds Assessment of Neuropathic Symptoms
and Signs (LANSS) scale for diagnosing NeP, and to fill out a questionnaire regarding the
management of NeP, together with a questionnaire evaluating the impact of pain on sleep and daily
life. Data on 2,480 pain patients were obtained. A LANSS score ≥ 12 (meaning NeP is most
probably present) was reported for 1,163 patients. Pathologies typically associated with NeP
scored above 12 on the LANSS scale, contrary to pathologies generally considered as being of non-
neuropathic origin.
Results: Over 90% of the patients with a LANSS score ≥ 12 reported that the pain impaired sleep.
A high impact on social, family and professional life was also recorded. Additional examinations
were performed in 89% of these patients. Most patients were taking multiple drugs, mainly
paracetamol and non-steroidal anti-inflammatory drugs, indicating that physicians generally tend to
follow treatment guidelines of chronic nociceptive pain, rather than the specific ones for NeP.
Specific neuropathic guidelines rather recommend the use of anti-epileptic drugs, tricyclic
antidepressants or weak opioids as first-line treatment.
Conclusion:  In our survey, application of the LANSS scale lead to pronounced treatment
simplification with fewer drug combinations. Awareness about NeP as well as its specific treatment
recommendations should be raised among healthcare providers. We concluded that the LANSS
screening scale is an interesting tool to assist physicians in detecting NeP patients in routine clinical
care.
Background
Neuropathic pain (NeP) has been defined by the Interna-
tional Association for the Study of Pain (IASP) as pain that
is initiated or caused by a primary lesion or dysfunction in
the nervous system [1]. NeP often manifests as spontane-
ous pain (e.g. burning, throbbing, shooting, electric shock
sensations), as well as pain that is provoked by stimuli
that are normally not painful (allodynia), or that elicit an
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exaggerated response to a painful stimulus (hyperalgesia)
[2]. NeP is thought to be present in ~25% of chronic pain
patients [3], but remains frequently undiagnosed. Hence,
treatment may often be inadequate [4,5]. NeP is often
associated with comorbid conditions such as poor sleep,
depression, mood disturbances, and a lowered quality of
life (QoL) [6].
Common causes of NeP include diabetes mellitus, cancer,
herpes zoster, trigeminal neuralgia, complex regional pain
syndrome (CRPS), alcohol abuse, multiple sclerosis (MS)
and other [7]. NeP is notoriously difficult to treat and
tends to be refractory to the analgesics commonly
employed for treating nociceptive pain (NocP), such as
paracetamol and non-steroidal anti-inflammatory drugs
(NSAIDs) [4,8]. In contrast, antiepileptic (anticonvul-
sant) drugs (AEDs), antidepressants, and some opioids
have proven efficacy against several manifestations of NeP
[4,9,10].
However, a major hurdle in establishing a correct diagno-
sis and hence to provide the patient with the appropriate
therapy is the lack of unambiguous diagnostic criteria for
distinguishing NeP from NocP. Physicians often rely on
the clinical diagnosis that may be complemented with
exams such as radiological examinations (RX, CT scan or
MRI), electromyography (EMG), or a somatosensory
evoked potential test. Recently, the Leeds Assessment of
Neuropathic Signs and Symptoms (LANSS) pain scale was
developed and validated to provide clinicians with a prac-
tical instrument for discriminating NeP from NocP in
daily practice [11]. The LANSS pain scale consists of two
parts: (1) a 5 item pain questionnaire that has to be com-
pleted by the patient, with queries about the nature of the
pain, and (2) a simple sensory testing part for assessing
the presence of allodynia and hyperalgesia that has to be
carried out by the physician [11]. The LANSS scale has
been previously employed in various pain states, such as
post-thoracotomy pain [12], low back pain [13], fibromy-
algia [14,15], and head and neck cancer [16].
The objective of this survey was to increase awareness of
NeP among Belgian physicians and to determine whether
a screening scale would be helpful in making the correct
diagnosis. Furthermore, we aimed to assess how NeP is
managed in Belgium, and how this condition affects the
quality of sleep and daily life in the patients. To our
knowledge, this is the first study to report on the use of a
pain scale in the diagnosis of NeP on a large scale in real-
life clinical practice.
Methods
Study design
One hundred and seventy seven general practitioners
(GP) and 97 specialists (mostly rheumatologists, pain
specialists and neurologists) participated in this study. In
Belgium (pain) patients can directly consult any specialist
of their choice, without prior referral by their GP. Because
GP's in Belgium often do not act as frontline physicians
for pain conditions – with pain patients immediately con-
tacting the specialists they consider appropriate for solv-
ing their problem – we believe that there is no major
difference in patient population nor pain characteristics in
the specialists' reception from those in GPs'. The study
was approved by the local ethics committee of the Ant-
werp University Hospital (UZA). Written informed con-
sent was obtained from all patients before their inclusion
in the study.
Participating physicians were instructed to document 15
consecutive  patients presenting with symptoms of sub-
acute (between 3 and 6 months of duration) and chronic
(> 6 months) pain in their practice, irrespective of the type
of pain (nociceptive or neuropathic). Pregnant and breast-
feeding women, and women who were planning to
become pregnant in the near future, were excluded from
the study. Age, gender, and duration of pain of all patients
were recorded. The possible underlying cause of the pain
was also documented by the physician.
The physicians were asked to fill out the LANSS question-
naire (characterization of the pain true 5 questions), as
well as to perform the two included items for sensory test-
ing: (1) allodynia and (2) altered pin-prick threshold.
Allodynia was judged to be present when pain was elicited
by gently stroking a piece of cotton wool over the painful
area and when normal sensation was experienced in the
control site. Hyperalgesia was judged to be present when
pin-prick testing elicited an exaggerated painful response
at the painful site compared with the control site. Valida-
tion of a Dutch and French version of the original (Eng-
lish) LANSS-scale was performed before the start of the
study, in accordance to how this validation was per-
formed for other languages [17,18]. Translation and back-
translation method was used to adapt the LANSS into
Dutch and French. In this process, the scale was first trans-
lated and culturally adapted into Dutch and French by a
translator who spoke English fluently (conceptual equiva-
lence approach). The scale was then back-translated into
English by a native English speaker who had not seen the
original English version. The back-translated English ver-
sion was then compared by several experts with the origi-
nal LANSS in English. Bilingual fluency was required for
all translators involved in this process.
For the patients who had a LANSS scale pain score ≥ 12
(meaning NeP is most probably present) the physicians
filled out an additional questionnaire providing more
detailed information on (1) previously performed and
future planned treatment options for the pain condition,BMC Public Health 2007, 7:170 http://www.biomedcentral.com/1471-2458/7/170
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(2) any additional tests that were performed for confirm-
ing the diagnosis and (3) the impact of the pain symp-
toms on sleep and activities of daily living. Although
useful information regarding treatment and functional
status could have been generated if all  patients would
have completed this additional questionnaire, due to
practical reasons (work load of participating physicians) it
was opted by the investigators not to obtain this addi-
tional information in patients with LANSS-scores < 12.
Sleep was assessed in a quantitative way by using a visual
analogue scale for sleep quality (VAS) offering a score
between 0 (no sleep disturbance) to 10 (maximal sleep
disturbance) for sleep disturbance during the past 24 h. In
addition, sleep was assessed qualitatively by asking the
patients which specific aspects of sleep were disturbed
(inability to fall asleep, frequent interruptions of sleep,
non-restorative sleep and premature awakenings). Finally,
patients were asked if their pain had an impact on follow-
ing aspects of daily life: family life, social activities, profes-
sional life and leisure.
Statistical analysis
Data analyses were based on descriptive statistics, includ-
ing percentages, medians, means, ranges and standard
deviations. Percentages were calculated based on all val-
ues for that particular question (missing excluded). Anal-
yses were performed on the total patient group as well as
the LANSS pain score subgroups (cut-off value at 12).
Comparison of parameters (duration of pain, age)
between LANSS pain score subgroups was carried out
Identified causes of pain Figure 1
Identified causes of pain. Possible underlying causes of pain in (1) all patients pooled (n = 2,436) and (2) the patients with a 
LANSS pain score ≥ 12 (n = 1,163). Patients may have multiple underlying pathologies. DN: diabetic neuropathy, TS: trigeminal 
syndrome (neuralgia); Ca: cancer, LP: lumbar pain, OP: osteoporosis; MS: multiple sclerosis, PHN: post-herpetic neuralgia, CRPS: complex 
regional pain syndrome; SM: Syringomyelia; CCS: carpal canal syndrome; pCVA: post-cerebrovascular accident; Alc: alcohol abuse; PSL: 
post-surgical lesions; PTL: post-traumatic lesion; OA: osteoarthritis.BMC Public Health 2007, 7:170 http://www.biomedcentral.com/1471-2458/7/170
Page 4 of 13
(page number not for citation purposes)
using t-test statistics. Fisher's exact test was employed for
assessing differences in gender and type of pain. All statis-
tical tests were interpreted at the 5% significance level
(two-tailed). In addition, odds ratios, together with 95%
confidence intervals, were calculated for the patients with
only one underlying cause of pain to investigate the influ-
ence of the underlying pathology on the LANSS pain
scores. Patients reporting multiple underlying causes of
pain were excluded from the odds ratio analysis to avoid
confounding effects of the various pathologies on the
LANSS score.
Results
Total patient population
In total 2,480 pain patients were enrolled in the study by
177 general practitioners (GPs) and 97 specialists. The
total number of patients that could have been expected
was not reached since 63 physicians (28 GP's and 35 spe-
cialists) failed to fulfil the inclusion target, and a number
of questionnaires (n = 493) had to be discarded due to
incompleteness of the data. Reasons for these failures are
probably the work load and the strict time schedule of this
protocol. Around two thirds of the patients (n = 1,649)
were treated by a GP, while 831 patients (34%) were
Calculated Odds ratios Figure 2
Calculated Odds ratios. Odds ratios for the various pathologies having a LANSS score ≥ 12 with 95% CI. Only patients with 
one cause of pain included (n = 1,510). Scale on x-axis has been cut off at 10 for better visualisation (note the logarithmic scale on 
the x-axis). Upper limit (UL) of confidence interval for MS = 20, and for SM = 61. DN: diabetic neuropathy, Ca: cancer, LP: lumbar 
pain, OP: osteoporosis; MS: multiple sclerosis, PHN: post-herpetic neuralgia, CRPS: complex regional pain syndrome; SM: Syringomyelia; 
CCS: carpal canal syndrome; pCVA: post-cerebrovascular accident; Alc: alcohol abuse; PSL: post-surgical lesions; PTL: post-traumatic 
lesions.BMC Public Health 2007, 7:170 http://www.biomedcentral.com/1471-2458/7/170
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being treated by a specialist. More than half of the partic-
ipating pain patients (59.6%) were women. The mean age
of the patients was 58.2 years (standard deviation, SD, =
15.7). The average duration of the pain amounted to 3.0
years (SD = 4.4), with a range from less than three months
to 60 years (diabetic neuropathy). Almost one third of the
patients (28%) reported their pain having lasted from six
months to three years.
Underlying pathologies
Data on the underlying pathology were obtained for
2,436 out of 2,480 pain patients (98%). A total of 65.2%
of the patients had one underlying cause of pain, while in
25.4% of patients two underlying disorders could be iden-
tified. Three or more pathologies were reported by 9.4%
of the patients. The most prevalent causes of pain con-
sisted of lumbar pain (32.1% of patients), followed by
osteoarthritis (OA) (24.2%), post-traumatic lesions
(13.4%), diabetes mellitus (10.4%), post-surgical lesions
(9.5%), osteoporosis (7.6%), complex regional pain syn-
drome (CRPS) (7.3%), and post-herpetic neuralgia
(6.7%) (Fig. 1). The most frequently described combina-
tion of diagnoses was lumbar pain in combination with
OA (reported in 6.0% of patients), followed by lumbar
pain combined with post-surgical lesions (1.9% of
patients). It Is important to mention that there were no
statistical differences between the pathologies diagnosed
by the GP's or the specialists, with both physicians groups
reporting similar percentages for the different patholo-
gies.
Type of pain symptoms
Spontaneous pain was present in 96.5% of the patients. A
total of 61.5% of patients seeking medical help reported a
combination of spontaneous and provoked pain symp-
toms (61.5%), while 37.8% reported spontaneous pain as
their only symptom. Finally, 0.7% of patients reported
only provoked pain symptoms. Spontaneous pain was
mainly described in terms of throbbing pain (61.3%), a
burning sensation (47.9%), or abnormal and disagreeable
(painful) sensations (dysaesthesia) (47.8%). Less fre-
quent manifestations of spontaneous pain comprised cut-
ting-lacerating pain (31.8% of patients), electric shock
sensation (22.8%), stab sensation (18.8%), and abnor-
mal but not disagreeable sensation (paraesthesia)
(17.3%). The majority of the patients with spontaneous
pain symptoms (57.7%) identified two or three terms to
describe their symptoms. The combination of a burning
sensation, throbbing pain and dysaesthesia was the most
frequently reported combination (6.4% of the patients
with spontaneous pain), followed by a burning sensation
together with dysaesthesia (4.5%), throbbing pain with
dysaesthesia (4.3%), and throbbing pain in combination
with cutting-lacerating pain symptoms (4.0%).
Evoked pain was mostly present as allodynia (40.3%),
hyperalgesic symptomatology only (10.3%), or mixed
allodynic/hyperalgesic symptoms (47.0%). Touch-evoked
allodynia was most common (71.7% of all patients suffer-
ing from provoked pain). These allodynic symptoms were
induced by several triggers, such as contact with clothes
(38.8%), or allodynia in the shower or in bath (15.2%),
followed by painful symptoms resulting from wind blow-
Table 1: Comparison of type of pain complaints between patients with LANSS score ≥ 12 and patients with a LANSS score < 12
Number (%) of patients 
with LANSS <12
Number (%) of patients with 
LANSS ≥ 12
Fischer's exact test
Patients with spontaneous pain complaints N = 1,238 N = 1,131
Burning sensation 351 (28.4%) 788 (69.7%) P < 0.001
Throbbing pain 757 (61.2%) 697 (61.6%) P = 0.833
Paraesthesia 231 (18.7%) 178 (15.7%) P = 0.064
Dysaesthesia 351 (28.4%) 782 (69.1%) P < 0.001
Cutting, lancinating pain 378 (30.5%) 375 (33.2%) P = 0.171
Stab sensation 187 (15.1%) 259 (22.9%) P < 0.001
Electric shock sensation 155 (12.5%) 387 (34.2%) P < 0.001
Other 117 (9.5%) 19 (1.7%) P < 0.001
Patients with complaints of provoked pain N = 458 N = 1,024
Allodynia to the touch 269 (58.7%) 795 (77.6%) P < 0.001
Allodynia to contact with wind 33 (7.2%) 150 (14.7%) P < 0.001
Allodynia to contact with clothes 88 (19.2%) 487 (47.6%) P < 0.001
Allodynia in the shower/bath 32 (7.0%) 191 (18.7%) P < 0.001
Allodynia to temperature 49 (10.7%) 47 (4.6%) P < 0.001
Allodynia to shaving 17 (3.7%) 62 (6.1%) P = 0.079
Hyperalgesia in contact with needle 129 (28.2%) 650 (63.5%) P < 0.001
Hyperalgesia to pressure 15 (3.3%) 22 (2.2%) P = 0.210BMC Public Health 2007, 7:170 http://www.biomedcentral.com/1471-2458/7/170
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ing against the face (12.5%) and during shaving (5.4%).
Pin-prick hyperalgesia was found to be the most common
form of hyperalgesia, being present in more than half
(52.5%) of all patients suffering from hyperalgesic symp-
toms. Other forms of hyperalgesia were reported in 2.5%
of the patients. Once more, as observed previously with
spontaneous pain, a majority of patients (61.6%)
reported more than one subtype of provoked pain. The
most frequently reported combinations of provoked pain
symptoms were touch-evoked allodynia combined with
pin-prick hyperalgesia (12.5% of the patients with pro-
voked pain symptoms), followed in second place by
touch-evoked allodynia combined with allodynia
induced by clothing and pin-prick induced hyperalgesia
(11.7%).
Subgroups of patients: LANSS scale pain score <12 versus 
LANSS scale pain score ≥ 12
Of the total number of patients enrolled in this survey for
whom a LANSS pain score was recorded (n = 2,464),
1,163 patients (47.2%) presented with a LANSS score of
12 or more (LANSS ≥ 12 group), which strongly suggests
the presence of a pain component of neuropathic origin
[11]. Demographic data were similar across the sub-
groups, showing no significant differences in age (mean
57.7 yrs, SD = 15.5 vs. 58.6 yrs, SD = 15.8; NS), gender
(58.5% vs. 60.5% women; NS), or duration of pain (mean
3.1 yrs, SD = 4.1 vs. 2.9 yrs, SD = 4.7; NS) between the
LANSS ≥ 12 group and the patients with a LANSS score <
12 (LANSS < 12 group) respectively. We did not find any
significant association between LANSS score and duration
of the pain in either subgroup (data not shown).
LANSS scale pain scores in relation to the underlying 
pathologies
Diseases that are known to be associated with NeP such as
diabetes mellitus (mean LANSS score = 14.4), syringomy-
elia (17.5), thalamic syndrome (18.1), post-herpetic neu-
ralgia (17.2), and CRPS type 2 (16.6) yielded higher mean
LANSS scores than pathologies that are generally consid-
ered to be associated with NocP, e.g. OA (mean LANSS
score = 8.7) or osteoporosis (9.2). Further support for the
efficacy of the LANSS scale in detecting NeP can be found
in the results of the odds ratio (OR) analysis, in which
1,580 patients reporting only one underlying cause of
pain were included. Indeed, the OR of having a LANSS
score ≥ 12 for patients suffering from a typical nociceptive
pathology, such as OA or osteoporosis, amounted to only
0.1 and 0.2 respectively, while the OR for NeP conditions
such as diabetic neuropathy, multiple sclerosis, post-her-
petic neuralgia and CRPS were 3.0, 6.9, 5.4, and 3.1
respectively (Fig. 2).
However, assessment of validity can not only be deter-
mined on the basis of averages of the LANSS scores
obtained for each clinical entity. In evident NeP syn-
dromes the LANSS Pain Scale failed to correctly identify
(score < 12) 25/133 of diabetic patients, 20/137 PHN
patients, 6/42 patients suffering from thalamic syndrome,
9/59 patients with carpal canal syndromes, 9/75 CRPS
patients, and 3/26 MS patients (all with only one pain
complaint). This amounts to a total number of failures of
72/472 (15,2%). In nociceptive syndromes, the LANSS
Pain Scale produced high scores (≥ 12) in 26/169 OA
patients, 68/316 patients suffering from lumbar pain, and
7/26 osteoporotic patients. In these three non-neuro-
pathic conditions, 101/511 received false high LANSS
scores (19,8%). When considering the above mentioned
NeP and NocP syndromes, the LANSS Pain Scale was able
to correctly identify 82,4% (810/983) of patients with one
pain complaint, representing 84,7% sensitivity and 80,2%
specificity.
Type of pain symptoms
The pattern in prevalence of specific subtypes of pain is
clearly different between the two subgroups of patients.
Data on type of pain were available for 1,245 patients
belonging to the LANSS < 12 group and for 1,140 patients
of the LANSS ≥ 12 group. Eighty-nine percent of the
patients belonging to the LANSS ≥ 12 group reported a
combination of stimulus-evoked and spontaneous pain,
against only 36.2% of those from the LANSS < 12 group.
In contrast, 63.2% of the patients of the LANSS < 12 group
reported only spontaneous pain, against 10.2% of those
in the LANSS ≥ 12 group. Isolated evoked pain complaints
were rather uncommon and their prevalence was similar
for both subgroups (0.6% and 0.8% of patients from the
LANSS < 12 and ≥ 12 groups respectively). In addition, the
various manifestations of spontaneous and provoked
pain syndromes were described in different terms by the
patients belonging to the different subgroups. Pain types
indicative of NeP occurred much more frequently in
patients with LANSS ≥ 12 than in those with a score of <
12 (Table 1). Indeed, more than twice the number of
patients from the LANSS ≥ 12 group than patients from
the LANSS < 12 group described their pain as a burning
sensation, dysaesthesia, and electric shock sensation
(Table 1). A stabbing sensation was also significantly
more prevalent among the patients belonging to the
LANSS ≥ 12 group compared to those belonging to the
LANSS < 12 group (22.9% vs. 15.1% of patients respec-
tively, p < 0.001). Most conditions of allodynia were also
significantly more prevalent among patients from the
LANSS ≥ 12 group than among those from the LANSS < 12
group (Table 1). Pin-prick evoked hyperalgesia was prev-
alent in about twice as many patients in the LANSS ≥ 12
group as in those in the LANSS < 12 group. In contrast, the
occurrence of other forms of hyperalgesia was not signifi-
cantly different between the two subgroups of patients
(Table 1).BMC Public Health 2007, 7:170 http://www.biomedcentral.com/1471-2458/7/170
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Impact of pain on sleep and daily life
Only patients belonging to the LANSS ≥ 12 group com-
pleted this part of the survey. Data on the effect of pain on
sleep was recorded for 1,148 of patients belonging to this
subgroup. The mean score for sleep disturbance on the
VAS amounted to 5.2 (SD = 2.6) on a scale from 0 to 10,
with 10 indicating a maximal sleep disturbance during the
past 24 h. It is important to mention that only 8.2% of all
patients completing the queries about their sleep quality
failed to report any negative impact of the pain symptoms
on their quality of sleep. Lumbar pain in combination
with post-surgical lesions was identified as the medical
condition that caused the most sleep disturbance with an
average VAS score of 6.0 (SD = 2.1, n = 27). The lowest
mean VAS score was found in the group of multiple scle-
rosis patients (mean VAS score = 4.1 SD = 2.6, n = 22).
Patients with combined complaints of spontaneous and
provoked pain had a mean VAS score of 5.3 (SD = 2.6; n
= 1,000), whereas patients with only spontaneous com-
plaints had a mean VAS score of 4.8 (SD = 2.4; n = 111).
Hyperalgesia and allodynia caused similar degrees of
sleep disturbance (mean VAS = 4.4, SD = 2.3, n = 74 and
mean VAS = 4.8, SD = 2.8, n = 320 respectively). When
considering the type of sleep interference, the large major-
ity of patients reported difficulties falling asleep (60.4%),
interruption of sleep (72.1%), premature awakening
(60.4%) and non-restorative sleep (66.7%). In addition,
93.6% of patients reported an impact on their activities of
daily living. Most of the patients reported an influence on
family life (77.5%), social activities (79.8%), spare time
(81.8%) and professional activities (66.1%). It should be
noted that 41.4% even reported influence of their pain on
all of these aspects.
Additional investigations
On top of the clinical examination, the large majority of
patients in the LANSS ≥ 12 group received complementary
technical investigations to obtain final confirmation of
the diagnosis of NeP. Data were available for 1,125 of the
patients in the LANSS ≥ 12 group, and revealed that 1,002
of these (89.1%) were subject to one of more supplemen-
tary examinations (besides clinical examination). The
most commonly performed technical investigations were
electromyography (68.9% of patients), followed by radi-
ography (59.2%), CT/MRI scan (56.2%), lab tests
(51.4%), bone scan (31.4%), and a sensory evoked poten-
tial test (8.5%). Of all patients subject to additional test-
ing, 77.8% received more than one test. Based on the
results of this study, post-herpetic neuralgia is apparently
perceived as the most straight-forward clinical diagnosis
since only less than half of these patients (44.9%) received
additional tests. In all other disorders a large majority of
patients was subject to additional exams. Interestingly,
our study results clearly indicate that the actual number of
additional tests that were carried out is highly dependent
on the underlying pathology. Most patients with carpal
canal syndrome (74.2%; 23 out of 31 patients) and
almost half of those suffering from diabetes (46.1%; 41
out of 89) received only one additional test, while the
majority of those with another underlying pathology
received two or more exams (Table 2).
Table 2: Percentage of patients undergoing one or more additional tests in relation to the underlying pathology in patients with 
LANSS ≥ 12 (n = 1,163)
Number of tests
P a t h o l o g y 0 12345 6
Diabetic neuropathy (n = 89) 6.7 46.1 19.1 10.1 11.2 6.7 0.0
Cancer (n = 27) 0.0 14.8 7.4 29.6 33.3 11.1 3.7
Lumbar problem (n = 84) 5.9 9.5 19.1 35.7 20.2 9.5 0.0
Osteoporosis (n = 3) 0.0 0.0 33.3 66.7 0.0 0.0 0.0
PHN (n = 98) 55.1 19.4 14.3 9.2 0.0 1.0 1.0
Multiple sclerosis (n = 22) 9.1 27.27 18.18 22.73 13.64 9.09 0.00
Post-traumatic lesion (n = 62) 6.4 19.3 19.3 17.7 20.9 16.1 0.0
Thalamic syndrome (n = 1) 0.0 0.0 0.0 0.0 0.0 100.0 0.0
CRPS (n = 51) 11.8 13.7 25.5 17.65 23.53 7.8 0.0
Alcohol (n = 17) 11.8 29.4 29.4 11.76 17.65 0.0 0.0
Syringomyelia (n = 6) 16.7 50.0 16.7 0.00 0.00 16.7 0.0
Post-surgical lesion (n = 34) 8.8 17.6 26.5 20.6 14.7 5.9 5.9
CCS (n = 31) 3.2 74.2 16.1 3.2 3.2 0.0 0.0
Osteoarthritis (n = 17) 11.8 5.9 23.5 17.6 23.5 11.8 5.9
Post-CVA (n = 24) 12.5 25.0 37.5 16.7 4.2 4.2 0.0
Others (n = 119) 13.4 25.2 21.8 20.2 10.9 6.7 1.7
Abbreviations: PHN: post-herpetic neuralgia; Post-CVA: post-cerebrovascular accident; CRPS: complex regional pain syndrome; CCS: carpal canal 
syndromeBMC Public Health 2007, 7:170 http://www.biomedcentral.com/1471-2458/7/170
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Pharmacological treatment of the pain
Previous treatment
In total, 95.1% of patients (n = 1,084) in the LANSS ≥ 12
group had received pharmacological treatment prior to
enrolment in this survey. In almost all patients this (pre-
vious) treatment consisted of prescription drugs (88.5%
of the patients) or a combination of prescription and
over-the-counter (OTC) drugs (9.8%). Paracetamol was
the most commonly prescribed drug (67.1% of the
patients) followed by drugs belonging to the non-selective
non-steroidal anti-inflammatory drugs (NSAID)/cyclo-
oxygenase-2 specific (COX-2) inhibitors (61.4%). On the
third place came the antidepressant agents (41.4%). Less
common were opioids (although still taken by about
30.5% of the patients), anti-epileptic drugs (AED) in
18.0% of the patients, and finally acetylic salicylic acid
(4.2%). Similar treatment patterns were found in patients
consulting a GP or a specialist. However, patients treated
by specialists received more treatments using AED than
when treated by primary care physicians (25.5% of
patients in specialist care versus 14.4% in primary care).
In contrast, the use of antidepressant drugs was more
common in patients seeking help of primary care physi-
cians than specialists (44.7% vs. 34.4%).
Only 24.1% of the patients had previously received one
drug, while 38.2% had been prescribed a combination of
two drugs, and 23.1% had even received three different
drugs (Fig. 3). Finally, 14.6% received a combination of
four or more medications. When treated with a combina-
tion of analgesics, the most frequently used combination
was paracetamol and NSAID/COX-2 inhibitors (14.6% of
patients), followed by a combination consisting of
NSAID/COX-2 inhibitors, paracetamol and antidepres-
Use of analgesic agents Figure 3
Use of analgesic agents. Number of pharmacological agents prescribed before and after applying the LANSS pain scale eval-
uation in LANSS ≥ 12 group.BMC Public Health 2007, 7:170 http://www.biomedcentral.com/1471-2458/7/170
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sive agents (8.9%). The use of paracetamol and NSAID
was fairly similar across underlying conditions (data not
shown) with about 60–75% of patients taking these
drugs. In contrast, considerable variations in the prescrip-
tion of opioids, AED and antidepressants were recorded
across the various pathologies. Opioids were the predom-
inant drugs in cancer pain conditions (62.8% of 47 cancer
patients) as well as in patients with post-surgical lesions
(44.0% of 134 patients). Antidepressant drugs were pre-
scribed to many patients suffering from MS (56.7% of 32
patients), post-herpetic neuralgia (49.6% of 127
patients), and pain due to a cerebrovascular accident
(post-CVA pain) (55.8% of 44 patients). AED were com-
monly taken by patients with post-CVA pain (48.8% of 44
patients), post-herpetic neuralgia (23.1% of 127
patients), post-surgical lesions (21.6% of 134 patients),
and in patients suffering from diabetic neuropathy
(18.6% of 160 patients).
Future treatment options
When questioned about which specific future treatment
options they considered appropriate for their patients,
physicians indicated that they considered pharmacologi-
cal treatment (either starting up or continuation) in
87.6% of the patients from the LANSS ≥ 12 group (n =
1,163). Interestingly enough, physicians stated that
respectively 36.6% and 17.6% of the patients would be
referred for physiotherapy and for psychosocial support.
Compared to previous treatment regimens, physicians
indicated that future treatment would consist of less drugs
being prescribed concomitantly (Fig. 3): whereas only
Current and future drug treatments Figure 4
Current and future drug treatments. Past and future treatment : proportion of patients taking only one drug who (1) will 
continue this treatment, (2) stop taking it, (3) who were not taking it but will start this treatment (4) who were not taking it 
and will not take it as new treatment. PAR: paracetamol; AD: antidepressive agent; OPIO: opioids; ASPI: aspirin (= acetylic sal-
icylic acid).BMC Public Health 2007, 7:170 http://www.biomedcentral.com/1471-2458/7/170
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24.1% of patients had received pharmacological mono-
therapy in the old regimen, 41.3% of patients would
receive only one drug after physicians had filled out the
LANSS questionnaire. New monotherapy would consist
mainly of AED (23.0%), followed by paracetamol (4.8%).
Treatment strategies before and after applying the LANSS
pain scale are illustrated in Fig. 4 (n = 930). Only about
half of the patients who previously received a pharmaco-
logical agent (paracetamol, NSAID/COX-2 inhibitors,
opioids, antidepressive agents, or AED) would continue
to receive the same drug in the future (Fig. 4). In contrast,
23.5% of patients would receive AED for the very first
time (180 out of 765 AED-naive patients).
Discussion
Progress in the further understanding of neuropathic pain
(NeP) in the general population has been seriously hin-
dered by a lack of epidemiologic research. One reason for
the lack of population-based epidemiologic data has been
the lack of a good case identification instrument for use in
surveys. In this study the Leeds Assessment of Neuro-
pathic Symptoms and Signs score (LANSS) was applied to
investigate the management of neuropathic pain in Bel-
gium. The LANSS scale was developed as a clinic based
instrument for identifying patients whose pain is domi-
nated by neuropathic mechanisms [11]. Although the
LANSS scale has been validated in different clinical set-
tings [11-17], it has never before been applied to such a
large sample from the general population. In addition,
our data collection was performed by a mixed group of
general practitioners and specialists, where previous stud-
ies always relied on a limited number of investigators to
administer the testing. Previous studies applied the LANSS
on selected patient populations [13,18], but its usefulness
was never really tested in routine clinical practice, nor in a
primary care setting. However, a general population sur-
vey was recently performed with the self-complete version
of the LANSS scale (S-LANSS) [19]. Finally, although this
study has a local setting (Belgium), we believe that most
of the results concerning diagnosis and management of
NeP can be extrapolated to other neighbouring countries.
The average age of the participating patients was 58 years,
and the majority were women. This is congruent with lit-
erature data showing that female gender and higher age
constitute major risk factors for chronic pain [20-22].
It is generally conceived that about 25% of all chronic
pain patients suffer NeP [3]. In our study however, almost
half of the pain patients presented with a LANSS score ≥
12. This unexpectedly high proportion of patients symp-
tomatic of NeP suggests that participating physicians per-
haps have preferentially included patients with NeP
symptoms (recruitment bias), despite the specific request
to include the first 15 pain patients presenting, irrespec-
tive of their specific complaints. However, the objective of
our study was not to estimate the prevalence of NeP, but
rather assessing the diagnosis and management of NeP in
Belgian practice. For purely practical reasons, it was
decided not to complete the additional questionnaires in
patients with LANSS scores < 12. This is without any
doubt a methodological limitation of the study, since it
could have been interesting to compare the treatment and
functional status of both neuropathic (NeP) and nocicep-
tive (NocP) pain patients in Belgium. However, demand-
ing that additional questionnaires would be completed
for  all  participating patients would have significantly
increased the physicians' work load, perhaps further
diminishing their preparedness to include sufficient
number of patients.
The use of a screening scale as instrument for helping to 
diagnose NeP
Bennett [11] reported a sensitivity and specificity of 83%
and 87% respectively for the LANSS scale. The purpose of
this study was not to validate the LANSS scale, but rather
to provide physicians with an instrument for assisting
them in the diagnosis of NeP. Average LANSS scores in
conditions associated with NeP such as diabetes and mul-
tiple sclerosis were well above 12, while non-neuropathic
conditions such as OA scored mean values below 12. Pain
symptoms known to be associated with NeP such as allo-
dynia, hyperalgesia, shooting pain, electric shock sensa-
tions, and burning and throbbing pain were significantly
more prevalent in patients with a LANSS pain score ≥ 12.
The results of the odds ratio analysis provide an even
stronger support for the relationship between a LANSS
score of ≥ 12 and NeP conditions. Limited number of
patients suffering from typical neuropathic pathologies
ended up with low LANSS-scores (15,2%), while patients
suffering from probable nociceptive pain conditions dis-
played high LANSS-scores in 20,3% of cases. These figures
provide important additional information regarding the
sensitivity and specificity of the LANSS-scale in patients
displaying one type of pain within our particular setting.
With the suggested cut-off score of 12, the LANSS Pain
Scale displayed a good sensitivity (84,7%) and only a
slightly lower specificity (80,2%). Sensitivity and specifi-
city is therefore largely comparable to those previously
reported in other studies [11,13,14,16,18]. This is a strong
indication that the LANSS-scale can be used in larger pop-
ulation samples and by different groups of physicians.
Nevertheless, not all patients with a typical neuropathic
condition actually do suffer from neuropathic pain symp-
toms. It is estimated that 75% of syringomyelia patients
and 20–24% of diabetes patients have NeP [4,23]. Taken
together, this data suggests that using a screening scale
such as the LANSS may prove a useful tool for discriminat-
ing between nociceptive and neuropathic pain in routine
clinical practice. The routine application of the LANSSBMC Public Health 2007, 7:170 http://www.biomedcentral.com/1471-2458/7/170
Page 11 of 13
(page number not for citation purposes)
scale could assist in modifying the analgesic approach to
these patients.
It should be noted that distribution of patient popula-
tions and pain characteristics did not differ significantly
between GP's and specialists. This should perhaps be con-
sidered a somewhat typical Belgian finding, since general
practitioners have no major gate-keeping role in the refer-
ral of patients to specialist care. In other countries (e.g.
The Netherlands) GP's tend to be much more in control
of this referral process, which probably leads to signifi-
cantly different patient populations and pain characteris-
tics in specialists' reception compared to those in GPs'. In
addition, no significant differences were observed in the
obtained LANSS-scores, which proves that this scale can
be used by a diverse group of physicians.
Post-herpetic neuralgia and diabetic neuropathy were the
most common underlying diagnoses in patients with
LANSS score ≥ 12 for whom one cause of pain was diag-
nosed. This is in line with data from other investigators
[3,5,20], and further supports the usefulness of the LANSS
scale for detecting NeP. The observation that the non-neu-
ropathic condition OA has been diagnosed in an appreci-
able proportion of (putative) NeP patients is consistent
with previously published data that NeP patients are dis-
proportionably affected by OA [20]. In addition, consid-
ering the relatively high average age of the patients (58
years), it can be expected that many of these may have OA
concomitantly with another (non-OA related) NeP condi-
tion. This is clearly reflected by the fact that almost 40%
of the patients with a LANSS score ≥ 12 present with mul-
tiple underlying causes of pain, some of which may be of
non-neuropathic origin. Indeed, physicians were
requested to record any possible cause of underlying pain
for all patients, regardless of whether or not it might be
related to NeP.
Considering the observation that almost 90% of the
patients with a LANSS score suggestive for the possible
presence of a neuropathic pain syndrome, still received
additional technical investigations, a more widespread
use of these types of screening scales may perhaps
decrease the need of additional medical exams and speed
up the implementation of neuropathic-specific treatment
regimens (although a definite or probable diagnosis of
neuropathic pain surely implies a proof of damage to the
somatosensory system by neuroimaging or electrophysi-
ology). It is of importance that NeP should be treated
promptly, because the longer the delay in appropriate
therapy, the lower the proportion of patients in whom the
NeP is relieved [3]. Fewer additional investigations would
significantly decrease the financial burden upon patient
and healthcare system. Patients with painful neuropathies
incur health care costs that are three times higher than
those without NeP [20].
Impact of NeP on sleep and daily life
The negative impact of chronic pain including NeP on
Quality of Life (QoL) is well documented. Chronic pain
adversely affects overall health, daily activities and pro-
ductivity at work, and is an important predisposing factor
for depression [21,24-26]. Daily chronic pain relates
stronger to poor health than chronic disease or age [25].
Our study results are consistent in that the majority of
(putative) NeP patients reported their pain affecting
social, family and professional life, and spare time. Like-
wise, the negative impact of the pain on sleep reported in
our survey is congruent with data showing that the large
majority of chronic pain patients report a considerable
degree of sleep disturbance [27]. However, the association
between sleep and chronic pain may be complex [27-29].
Firstly, chronic pain results often in mood disturbances,
anxiety and depression [6], disorders that in turn nega-
tively impact sleep [30]. Secondly, lack of sleep decreases
pain thresholds and leads to increased pain perception
[31,32], and/or diminishes the patient's ability to cope
with pain. Furthermore, sleep deprivation is associated
with a decreased QoL along with a poor mental and
somatic health [33,34]. Hence, the sleep disruption
caused by chronic pain may predispose patients for addi-
tional morbidity. Consequently, alleviating NeP will
likely result in improved QoL. A concomitant increase in
QoL scores including sleep, activity and mood is observed
following a significant relief of the NeP [4,35].
Treatment of NeP in Belgian routine practice
Recent recommendations for the treatment of NeP suggest
the use of AED (gabapentin, carbamazepine and others),
tramadol, the 5% lidocaine patch or antidepressants as a
first-line therapy for NeP [8-10]. It should be borne in
mind however, that no antineuropathic drug is effective
against all manifestations of NeP [4], and that patients
with identical NeP conditions may respond quite differ-
ently to the same pharmacological approach [36]. Fur-
thermore, potential side effects associated with
antineuropathic drugs should be taken into account when
deciding upon the appropriate treatment. Patients who
are refractory to any first-line therapy may benefit from
other AED or antidepressant drugs, the combination of
several anti-neuropathic drugs, or may have to be referred
to a multidisciplinary pain centre [8,10].
The data obtained in our study shows that in Belgium NeP
is still mainly managed with conventional analgesics such
as paracetamol and NSAIDs, instead of the more effective
anti-neuropathic drugs. A widespread use of conventional
analgesics in the treatment of NeP has been reported by
others [4,5,20]. Gilron et al. [5] reported that 25% of neu-BMC Public Health 2007, 7:170 http://www.biomedcentral.com/1471-2458/7/170
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ropathic pain patients in their survey had never tried any
antineuropathic drugs, despite 73% of respondents com-
plaining of inadequate pain control; almost half of NeP
patients (47%) took paracetamol or NSAID. It has been
suggested that healthcare providers might feel more com-
fortable in prescribing traditional analgesics for the treat-
ment of pain, irrespective of its origin [20]. The limited
efficacy of these conventional analgesics in the treatment
of NeP may be reflected in the high prevalence of (con-
ventional drug type) combinations reported in our study:
three quarters of the patients with a LANSS score ≥ 12 who
received pharmacological treatment, initially received at
least two different analgesic drugs, while over one third
had even received combinations of three or more drugs.
However, upon completing the LANSS questionnaire, a
treatment simplification with a reduction in the number
of drug combinations was apparent. Especially AED had
become the drugs of choice as monotherapy. This may
reflect some increased awareness among physicians about
NeP. It is tempting to speculate that the request to employ
the LANSS scale as an aid in the diagnosis of chronic pain
may have brought the topic of NeP and its specific treat-
ment options to the attention of the physicians.
Conclusion
In conclusion, our study results confirm previous reports
that NeP is under-recognised and often not treated ade-
quately in daily practice, and that it has a considerably
negative impact on QoL. NeP patients are treated mainly
with combinations of conventional analgesics rather than
the more effective antineuropathic drugs, indicating that
physicians often do not follow the guidelines for NeP.
Clearly, awareness among physicians about NeP and the
availability of diagnostic tools should be augmented, and
the importance of applying appropriate treatment regi-
mens tailored to the individual patient's needs should be
more strongly emphasised. The results of this study indi-
cate that the LANSS-scale is a useful tool to discriminate
patients with a neuropathic pain component and to assist
in modifying the analgesic approach to these critical pain
syndromes.
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